Skip to content
Insider tapeFilings through Fri, Oct 9
Watchlist

Purchase track record

Not enough history. Based on 0 purchases with a full 90 days of price history.

—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $50K

Reported trades

Filed Stock Type Shares Price Value Since
Jan 23SEC ABOSAcumen Pharmaceuticals, Inc. Sell Plan 2,473306,611 held (−1%) $1.81 $4K +18.2%
Jan 23SEC ABOSAcumen Pharmaceuticals, Inc. Sell Plan 1,687304,924 held (−1%) $1.86 $3K +15.1%
Jan 12SEC ABOSAcumen Pharmaceuticals, Inc. Sell Plan 6,888209,951 held (−3%) $1.82 $13K +17.6%
Jan 7SEC ABOSAcumen Pharmaceuticals, Inc. Sell Plan 4,000227,744 held (−2%) $1.96 $8K +9.2%
Jan 7SEC ABOSAcumen Pharmaceuticals, Inc. Sell Plan 5,100222,644 held (−2%) $1.97 $10K +8.6%
Jan 7SEC ABOSAcumen Pharmaceuticals, Inc. Sell Plan 4,105218,539 held (−2%) $2.00 $8K +7.0%
Jan 7SEC ABOSAcumen Pharmaceuticals, Inc. Sell Plan 1,700216,839 held (−1%) $1.99 $3K +7.5%
  • Sell

    CFO Matt Zuga sold $4K of ABOS at $1.81 — pre-scheduled 10b5-1 plan sale.

  • Sell

    CFO Matt Zuga sold $3K of ABOS at $1.86 — pre-scheduled 10b5-1 plan sale.

  • Sell

    CFO Matt Zuga sold $13K of ABOS at $1.82 — pre-scheduled 10b5-1 plan sale.

  • Sell

    CFO Matt Zuga sold $8K of ABOS at $1.96 — pre-scheduled 10b5-1 plan sale.

  • Sell

    CFO Matt Zuga sold $10K of ABOS at $1.97 — pre-scheduled 10b5-1 plan sale.

  • Sell

    CFO Matt Zuga sold $8K of ABOS at $2.00 — pre-scheduled 10b5-1 plan sale.